Latest news with #securitiesfraud
Associated Press
18 hours ago
- Business
- Associated Press
Berger Montague Investigates Hims & Hers Health Inc. (HIMS) for Securities Fraud Following Termination of Novo Nordisk Partnership
Philadelphia, Pennsylvania--(Newsfile Corp. - June 27, 2025) - Berger Montague, a national securities litigation law firm, is investigating potential securities fraud claims against Hims & Hers Health Inc. ('Hims & Hers' or the 'Company') (NYSE: HIMS). Investor Deadline: Investors who purchased or acquired Hims & Hers securities between April 29, 2025 and June 22, 2025 (the 'Class Period') may, no later than August 25, 2025, seek to be appointed as a lead plaintiff representative of the class. To learn your rights,CLICK HERE. On June 23, 2025, Novo Nordisk announced the termination of its partnership with Hims & Hers, alleging that the company engaged in deceptive marketing and sold unapproved compounded versions of semaglutide. Following the announcement, shares of Hims & Hers declined by over 34% in intraday trading, reflecting investor concerns regarding regulatory compliance and reputational risks. This suit alleges throughout the Class Period, Hims & Hers made materially false or misleading statements or omitted material information regarding the nature and regulatory status of its GLP-1 offerings, the associated risks, and the partnership with Novo Nordisk. The firm is examining whether Hims & Hers and certain executives violated federal securities laws by making false or misleading statements to investors. If you are a Hims & Hers investor and would like to learn more about this action,CLICK HEREor please contact Berger Montague: Andrew Abramowitz at[email protected]or (215) 875-3015, or Caitlin Adorni at[email protected]or (267)764-4865. About Berger Montague Berger Montague, with offices in Philadelphia, Minneapolis, Delaware, Washington, D.C., San Diego, San Francisco and Chicago, has been a pioneer in securities class action litigation since its founding in 1970. Berger Montague has represented individual and institutional investors for over five decades and serves as lead counsel in courts throughout the United States. For more information or to discuss your rights, please contact: Andrew Abramowitz, Senior Counsel Berger Montague (215) 875-3015 [email protected] Caitlin Adorni Berger Montague (267) 764-4865 [email protected] To view the source version of this press release, please visit
Associated Press
a day ago
- Business
- Associated Press
NYSE: BRBR Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages BellRing Brands, Inc. (NYSE: BRBR) Investors with Significant Losses to Contact the Firm
RADNOR, Pa.--(BUSINESS WIRE)--Jun 27, 2025-- The law firm of Kessler Topaz Meltzer & Check, LLP ( ) is currently investigating potential violations of the federal securities laws on behalf of investors of BellRing Brands, Inc. ( NYSE: BRBR ) ('BellRing Brands'). On May 6, 2025, during its second quarter 2025 earnings call, BellRing Brands revealed that certain customers were now choosing to 'optimize' their inventories by lowering 'their weeks of supply on hand.' As a result, BellRing Brands disclosed that this would slow sales growth in the third quarter to 'low-single-digits.' On this news, the price of BellRing Brands' stock fell by nearly 19%, from a close of $78.43 on May 5, 2025, to close at $63.55 on May 6, 2025. If you are a BellRing Brands investor and would like to learn more about our investigation, pleaseCLICK HEREto fill out our online form or contact Kessler Topaz Meltzer & Check, LLP: Jonathan Naji, Esq. (484) 270-1453 or E-mail at[email protected].You can also click on the following link or paste it in your browser: Kessler Topaz Meltzer & Check, LLP prosecutes class actions in state and federal courts throughout the country involving securities fraud, breaches of fiduciary duties and other violations of state and federal law. Kessler Topaz Meltzer & Check, LLP is a driving force behind corporate governance reform, and has recovered billions of dollars on behalf of institutional and individual investors from the United States and around the world. The firm represents investors, consumers and whistleblowers (private citizens who report fraudulent practices against the government and share in the recovery of government dollars). For more information about Kessler Topaz Meltzer & Check, LLP, please visit May be considered attorney advertising in certain jurisdictions. Past results do not guarantee future outcomes. View source version on CONTACT: Kessler Topaz Meltzer & Check, LLP Jonathan Naji, Esq. 280 King of Prussia Road Radnor, PA 19087 (484) 270-1453 [email protected] KEYWORD: UNITED STATES NORTH AMERICA PENNSYLVANIA INDUSTRY KEYWORD: CLASS ACTION LAWSUIT PROFESSIONAL SERVICES LEGAL SOURCE: Kessler Topaz Meltzer & Check, LLP Copyright Business Wire 2025. PUB: 06/27/2025 11:06 AM/DISC: 06/27/2025 11:06 AM
Associated Press
3 days ago
- Business
- Associated Press
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Vestis Corporation (VSTS) Shareholders
NEW YORK - June 25, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Vestis Corporation ('Vestis' or the 'Company') (NYSE: VSTS) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Vestis investors who were adversely affected by alleged securities fraud between May 2, 2024 and May 6, 2025. Follow the link below to get more information and be contacted by a member of our team: VSTS investors may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500. CASE DETAILS: According to the complaint, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of Vestis' ability to grow its business; notably that Vestis would be unable to execute on planned strategic initiatives to drive purported improvements to the customer experience and its onboarding efforts in order to drive new customer growth, increased customer retention, and increased revenue from existing May 7, 2025, Vestis announced its financial results for the second quarter of fiscal 2025, withdrew its revenue and growth guidance for the full fiscal year 2025, and provided guidance for the third quarter of fiscal 2025 that fell significantly below market expectations. The Company attributed its poor results partially to 'lost business in excess of new business,' but primarily on 'lower adds over stops, which is how we describe volume changes with our existing customers.' The Company attributed its decision to pull full-year guidance and provide disappointing third quarter targets to the 'increasingly uncertain macro environment.'Following this news, the price of Vestis' common stock declined dramatically. From a closing market price of $8.71 per share on May 6, 2025, Vestis' stock price fell to $5.44 per share on May 7, 2025, a decline of about 37.54% in the span of just a single day. WHAT'S NEXT? If you suffered a loss in Vestis during the relevant time frame, you have until August 8, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. To learn more about this case, subscribe to the Bulls & Betrayals podcast, which features a dedicated episode unpacking the allegations against Vestis. Listen now and find out if you are eligible to join the lawsuit. NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate. WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. Ed Korsinsky, Esq. 33 Whitehall Street, 17th Floor New York, NY 10004 [email protected] Tel: (212) 363-7500 Fax: (212) 363-7171 View the original release on
Associated Press
3 days ago
- Business
- Associated Press
Contact Levi & Korsinsky by August 4, 2025 Deadline to Join Class Action Against Reckitt Benckiser Group plc (RBGLY)
NEW YORK - June 25, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Reckitt Benckiser Group plc ('Reckitt Benckiser Group plc' or the 'Company') (OTC PINK: RBGLY) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Reckitt Benckiser Group plc investors who were adversely affected by alleged securities fraud between January 13, 2021 and July 28, 2024. Follow the link below to get more information and be contacted by a member of our team: RBGLY investors may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500. CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (1) preterm infants were at an increased risk of developing NEC by consuming Reckitt's cow's milk-based formula, Enfamil; (2) of the attendant impact on Reckitt's sales of Enfamil and Reckitt's exposure to legal claims; and (3) as a result of the above, defendants' positive statements about the Company's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. WHAT'S NEXT? If you suffered a loss in Reckitt Benckiser Group plc during the relevant time frame, you have until August 4, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. To learn more about this case, subscribe to the Bulls & Betrayals podcast, which features a dedicated episode unpacking the allegations against Reckitt Benckiser Group plc. Listen now and find out if you are eligible to join the lawsuit. NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate. WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. Ed Korsinsky, Esq. 33 Whitehall Street, 17th Floor New York, NY 10004 [email protected] Tel: (212) 363-7500 Fax: (212) 363-7171 View the original release on
Associated Press
4 days ago
- Business
- Associated Press
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of August 8, 2025 in PepGen Inc. Lawsuit
NEW YORK - June 24, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in PepGen Inc. ('PepGen Inc.' or the 'Company') (NASDAQ: PEPG) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of PepGen Inc. investors who were adversely affected by alleged securities fraud between March 7, 2024 and March 3, 2025. Follow the link below to get more information and be contacted by a member of our team: PEPG investors may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500. CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (i) the Company's lead product candidate, PGN-EDO51, was less effective and safe than defendants had led investors to believe; (ii) phase two, CONNECT2 study was dangerous or otherwise deficient for purposes of U.S. Food and Drug Administration ('FDA') approval; (iii) as a result of all the foregoing, PepGen was likely to halt the CONNECT2 study, and PGN-EDO51's clinical, regulatory, and commercial prospects were overstated; and (iv) as a result, defendants' public statements were materially false and misleading at all relevant times. WHAT'S NEXT? If you suffered a loss in PepGen Inc. during the relevant time frame, you have until August 8, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. To learn more about this case, subscribe to the Bulls & Betrayals podcast, which features a dedicated episode unpacking the allegations against PepGen Inc.. Listen now and find out if you are eligible to join the lawsuit. NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate. WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. Ed Korsinsky, Esq. 33 Whitehall Street, 17th Floor New York, NY 10004 [email protected] Tel: (212) 363-7500 Fax: (212) 363-7171
